Otsuka, Horizon team up on early-stage development

Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments. Under the agreement, Horizon well lend out its tools for screening compounds and analyzing potential drug combinations, using technology it acquired in an $8 million buyout of Zalicus' ($ZLCS) CombinatoRx business earlier this year. The Otsuka deal is Horizon's first major partnership since pulling off a £68.6 million ($116.6) IPO in March. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.